Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)

BACKGROUND: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease and the most common systemic disorder associated with uveitis in childhood. Uveitis is more common in JIA patients who are antinuclear antibody (ANA)-positive, have an early-onset disease, and have oligoar...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramanan, Athimalaipet V., Guly, Catherine M., Keller, Stuart Y., Schlichting, Douglas E., de Bono, Stephanie, Liao, Ran, Quartier, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502273/
https://www.ncbi.nlm.nih.gov/pubmed/34627340
http://dx.doi.org/10.1186/s13063-021-05651-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502273/
https://www.ncbi.nlm.nih.gov/pubmed/34627340
http://dx.doi.org/10.1186/s13063-021-05651-5

Ejemplares similares